Related Experiment Video
Updated: Jan 27, 2026

The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability
Published on: April 28, 2022
Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist
Chu-Biao Xue1, Anlai Wang1, Qi Han1
1Incyte Corporation , Experimental Station E336, Wilmington, Delaware 19880, United States.
Abstract:
We report the discovery of a new (S)-3-aminopyrrolidine series of CCR2 antagonists. Structure-activity relationship studies on this new series led to the identification of 17 (INCB8761/PF-4136309) that exhibited potent CCR2 antagonistic activity, high selectivity, weak hERG activity, and an excellent in vitro and in vivo ADMET profile. INCB8761/PF-4136309 has entered human clinical trials.
Related Concept Videos
Bioavailability: Overview
Bioavailability: Influencing Factors
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Bioavailability: Overview

